Clinical trial
A Pilot Phase 2, Randomized, Double-Blind, Placebo-Controlled, Multi-Centered Safety, Tolerability and Preliminary EffiCacy Study of K201 Oral for the Prevention of ATrial FIbrillation (AF) Recurrence in Subjects Post-Conversion From AF
NCT01067833 is registered in ClinicalTrials.gov with Sequel Pharmaceuticals, Inc as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Pilot Phase 2, Randomized, Double-Blind, Placebo-Controlled, Multi-Centered Safety, Tolerability and Preliminary EffiCacy Study of K201 Oral for the Prevention of ATrial FIbrillation (AF) Recurrence in Subjects Post-Conversion From AF
- Lead sponsor
- Sequel Pharmaceuticals, Inc
- Phase
- Phase 2
- Overall status
- Terminated
- Start date
- April 30, 2010
- Completion date
- December 31, 2011
- Enrollment
- 300 (estimated)
- Sites
- Not reported
Conditions
As the registry lists them; a condition with its own page is linked.